06 March, 2020. View GWPH's stock ratings, price targets, earnings, commentary and news at Smarter Analyst. Out of 7 analysts covering the stock, GWPH has a consensus analyst rating of Strong Buy with an average price target of $182.67. Yahoo is part of Verizon Media. The table shows the mean historical analyst recommendation for the current period, along with the previous 1, 2, and 3 periods. To enable Verizon Media and our partners to process your personal data select 'I agree', or select 'Manage settings' for more information and to manage your choices. By creating an account, you agree to theTerms of Service and acknowledge our Privacy Policy. See GW Pharmaceuticals Plc (GWPH) stock analyst estimates, including earnings and revenue, EPS, upgrades and downgrades. The origin is having network or application issues. Following Justin Gover’s last GWPH Sell, Today it was reported that the Chief Commercial Officer of GW Pharma (GWPH – Research Report), Darren Cline, exercised options to sell 150 GWPH shares for a total transaction value of $18.97K. Based on analysts offering 12 month price targets for GWPH in the last 3 months. GW Pharma (GWPH) PT Raised to $154 at Cantor Fitzgerald. Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for how outside industry experts are weighing in on a stock. The company’s shares closed last Thursday at $132.10. GW Pharma (NASDAQ: GWPH) stock research, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers on Benzinga. That would be GWPH’s first flat quarter as the company moves closer to profitability. GW Pharma Analyst Expects $475M In Sales Of CBD Drug Expidiolex This Year (Analyst Color, Cannabis, GWPH, Price Target, Reiteration, Markets, Analyst Ratings / Thu, 01:16pm) Thursday, January 02, 2020 Unlike Barchart Opinions (which calculate the Buy/Sell rating using a variety of short-medium and long-term technical indicators), the Analyst Ratings are more of a short-term indicator that gives you a feel for … AUD/USD Forecast: Still Biased Lower And Poised To Test The 0.7... EUR/USD Forecast: Maintains Its Bearish Stance Despite Parin... Privacy Policy / Do Not Sell My Personal Data. Following Volker Knappertz’s last GWPH Sell transaction on May 21, 2020, the stock climbed by 4.5%. Barchart provides Analyst Ratings to give you another tool to gauge the possible future performance of a stock. Those same analysts give the stock an average rating of Strong Buy. The Chief Legal Officer of GW Pharma is Exercising Options, Merrill Lynch Reaffirms Their Buy Rating on GW Pharma (GWPH), GW Pharma (GWPH) Gets a Buy Rating from Oppenheimer, The Chief Medical Officer of GW Pharma (NASDAQ: GWPH) is Selling Shares, The Chief Executive Officer of GW Pharma is Exercising Options, The Chief Commercial Officer of GW Pharma is Exercising Options. Volume reflects consolidated markets. View today's stock price, news and analysis for GW Pharmaceuticals PLC ADR (GWPH). Analyst Ratings GW Pharmaceuticals PLC- (NASDAQ:GWPH) Price Target and Consensus Rating 13 Wall Street analysts have issued ratings and price targets for GW Pharmaceuticals PLC- in the last 12 months. View GWPH revenue estimates and earnings estimates, as well as analyst recommendations. Analyst Ratings are available for US and Canadian equities.